Moderna has reported some more good news from its trials, stating that its Covid-19 vaccine candidate has a final efficacy of just over 94 percent with nobody who received it during trials falling severely ill. That has paved the way for the company to apply for emergency usage authorization in the U.S. and Europe. That puts Moderna around a week behind Pfizer and BioNTech who already took that step with their own vaccine that emerged from trials with an efficacy of 95 percent.
With the pandemic worsening and the race to roll out the first vaccine heating up, Statista's Niall McCarthy notes that governments around the world have already reserved close to 10 billion doses before a single candidate has even reached the market. 2.6 billion further doses are under negotiation or reserved as optional expansions of existing deals. The findings come from Duke University who have been aggregating and analyzing publicly available data on vaccine procurement and manufacturing.
Read more ....
WNU Editor: I recall around March/April of this year most experts on vaccines were predicting a vaccine will only be administered at the end of 2021/beginning of 2022. They were wrong. This is an incredible medical/scientific accomplishment that will save countless lives and will get the world back to normal sooner rather than later.
Update: Here is a must read post from France's news agency explaining why President Trump deserves credit for this accomplishment .... US Operation Warp Speed backed vaccines for whole world (AFP).
No comments:
Post a Comment